First Time Loading...
Z

Zhejiang Hisun Pharmaceutical Co Ltd
SSE:600267

Watchlist Manager
Zhejiang Hisun Pharmaceutical Co Ltd
SSE:600267
Watchlist
Price: 8.33 CNY 2.08% Market Closed
Updated: May 6, 2024
Section:
 

Relative Value

The Relative Value of one Zhejiang Hisun Pharmaceutical Co Ltd stock under the Base Case scenario is 21.95 CNY. Compared to the current market price of 8.33 CNY, Zhejiang Hisun Pharmaceutical Co Ltd is Undervalued by 62%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
21.95 CNY
Undervaluation 62%
Relative Value
Price
Z
Worst Case
Base Case
Best Case

Valuation Multiples

0.8
P/S
P/S
Price to Sales
0.8
vs History
92
vs Industry
76
Median 3Y
1.1
Median 5Y
1.1
Industry
2.5
Forward
0.7
More Details
15.6
P/E
P/E
Price to Earnings
15.6
vs History
68
vs Industry
31
Median 3Y
25.4
Median 5Y
24
Industry
23.4
Forward
18.4
More Details
5
P/OCF
P/OCF
Price to OCF
5
vs History
92
vs Industry
45
Median 3Y
6.6
Median 5Y
8.8
Industry
17.4
More Details
6
P/FCFE
P/FCFE
Price to FCFE
6
vs History
25
vs Industry
33
Median 3Y
-14
Median 5Y
-9.1
Industry
23.6
More Details
1.1
P/B
P/B
Price to Book Value
1.1
vs History
92
vs Industry
59
Median 3Y
1.6
Median 5Y
1.7
Industry
2.1
More Details
1.1
EV/S
EV/S
Enterprise Value to Sales
1.1
vs History
92
vs Industry
70
Median 3Y
1.5
Median 5Y
1.7
Industry
2.6
Forward
1.1
More Details
2.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.7
vs History
92
vs Industry
65
Median 3Y
3.7
Median 5Y
3.9
Industry
5.2
More Details
13.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
13.5
vs History
73
vs Industry
28
Median 3Y
17.3
Median 5Y
17.3
Industry
13.7
Forward
6.3
More Details
13.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
13.5
vs History
73
vs Industry
33
Median 3Y
17.3
Median 5Y
17.3
Industry
17.2
Forward
11.8
More Details
7.1
EV/OCF
EV/OCF
Enterprise Value to OCF
7.1
vs History
92
vs Industry
43
Median 3Y
8.8
Median 5Y
12.8
Industry
16.2
More Details
8.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
8.8
vs History
73
vs Industry
31
Median 3Y
11.7
Median 5Y
11.7
Industry
17.8
More Details
0.9
EV/IC
EV/IC
Enterprise Value to IC
0.9
vs History
85
vs Industry
63
Median 3Y
1.1
Median 5Y
1.1
Industry
2
More Details

Multiples Across Competitors

Competitors Multiples
Zhejiang Hisun Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Zhejiang Hisun Pharmaceutical Co Ltd
SSE:600267
9.6B CNY 0.8 15.6 13.5 13.5
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
716.9B USD 20 116.8 57.2 65.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.8T DKK 16.4 45.4 33.2 36.2
US
Johnson & Johnson
NYSE:JNJ
356.2B USD 4.2 9.3 11.4 14.9
US
Merck & Co Inc
NYSE:MRK
321.2B USD 5.2 139.3 33.2 52.6
UK
AstraZeneca PLC
LSE:AZN
186.8B GBP 5.1 39.4 140.7 225.7
CH
Novartis AG
SIX:NOVN
180B CHF 4.3 13.4 9.8 16.2
CH
Roche Holding AG
SIX:ROG
174.5B CHF 3 15.2 8.6 10.3
US
Pfizer Inc
NYSE:PFE
158.8B USD 2.9 -513.9 12.8 20.3
P/E Multiple
Earnings Growth
CN
Z
Zhejiang Hisun Pharmaceutical Co Ltd
SSE:600267
Average P/E: 49.3
15.6
4%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
116.8
346%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
45.4
84%
US
Johnson & Johnson
NYSE:JNJ
9.3
-20%
US
Merck & Co Inc
NYSE:MRK
139.3
7 454%
UK
AstraZeneca PLC
LSE:AZN
39.4
168%
CH
Novartis AG
SIX:NOVN
13.4
15%
CH
Roche Holding AG
SIX:ROG
15.2
26%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -513.9
680%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 134,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.